Oak Grove Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Oak Grove Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.34M	Hold	1,730	–	–	0.11%	51
2025 Q4	$1.34M	Sell	1,730 -50	-3%	-$34K	0.16%	44
2025 Q3	$1M	Sell	1,780 -800	-31%	-$452K	0.14%	42
2025 Q2	$1.35M	Sell	2,580 -450	-15%	-$251K	0.22%	41
2025 Q1	$1.92M	Buy	3,030 +100	+3%	+$68.8K	0.4%	32
2024 Q4	$2.09M	Buy	2,930 +950	+48%	+$797K	0.31%	38
2024 Q3	$2.08M	Buy	1,980 +80	+4%	+$89K	0.34%	33
2024 Q2	$2M	Buy	+1,900	New	+$1.84M	0.36%	32
2022 Q2	–	Sell	-670	Closed	-$468K	–	77
2022 Q1	$468K	Sell	670 -300	-31%	-$190K	0.09%	61
2021 Q4	$613K	Sell	970 -50	-5%	-$30.7K	0.11%	67
2021 Q3	$617K	Buy	1,020 +80	+9%	+$49.7K	0.13%	64
2021 Q2	$525K	Buy	940 +220	+31%	+$111K	0.12%	70
2021 Q1	$341K	Buy	+720	New	+$351K	0.1%	72

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Oak Grove Capital's REGN Position: Q1 2026 in Review

Oak Grove Capital held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2026 at 1,730 shares worth $1.34M. The position accounts for 0.11% of the portfolio, ranked #51.

Oak Grove Capital first reported a position in REGN in Q1 2021 and has held it in 13 quarters since. The position peaked at $2.09M in Q4 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Oak Grove Capital held 1,730 shares of Regeneron Pharmaceuticals worth $1.34M as of Q1 2026.
Oak Grove Capital left its Regeneron Pharmaceuticals share count unchanged in Q1 2026.
Regeneron Pharmaceuticals made up 0.11% of Oak Grove Capital's portfolio in Q1 2026, its #51 holding.
Oak Grove Capital first reported a position in Regeneron Pharmaceuticals in Q1 2021 and has held it in 13 quarters since.
Oak Grove Capital's Regeneron Pharmaceuticals position peaked at $2.09M in Q4 2024.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Oak Grove Capital's 13F filing for Q1 2026, filed 13 May 2026.